Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ARQT

ARQT - Arcutis Biotherapeutics Inc Stock Price, Fair Value and News

9.74USD-0.03 (-0.31%)Market Closed

Market Summary

ARQT
USD9.74-0.03
Market Closed
-0.31%

ARQT Stock Price

View Fullscreen

ARQT RSI Chart

ARQT Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-5.19

Price/Sales (Trailing)

10.6

Price/Free Cashflow

-5.68

ARQT Price/Sales (Trailing)

ARQT Profitability

Operating Margin

96.97%

Return on Equity

-96.66%

Return on Assets

-45.43%

Free Cashflow Yield

-17.62%

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

106.4M

Rev. Growth (Yr)

1.7K%

Rev. Growth (Qtr)

266.47%

ARQT Earnings

Earnings (TTM)

-217.4M

Earnings Growth (Yr)

55.83%

Earnings Growth (Qtr)

46.62%

Breaking Down ARQT Revenue

Last 7 days

-8.3%

Last 30 days

19.5%

Last 90 days

7.0%

Trailing 12 Months

-6.0%

How does ARQT drawdown profile look like?

ARQT Financial Health

Current Ratio

9.89

Debt/Equity

0.9

Debt/Cashflow

-0.98

ARQT Investor Care

Shares Dilution (1Y)

88.47%

Diluted EPS (TTM)

-2.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024106.4M000
202317.7M31.6M45.6M59.6M
20220003.7M

Tracking the Latest Insider Buys and Sells of Arcutis Biotherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 01, 2024
welgus howard g.
acquired
16,806
1.6806
10,000
-
Jul 01, 2024
welgus howard g.
sold
-93,141
9.3141
-10,000
-
Jun 14, 2024
welgus howard g.
acquired
-
-
10,139
-
Jun 14, 2024
curran terrie
acquired
-
-
10,139
-
Jun 14, 2024
lin sue-jean
acquired
-
-
10,139
-
Jun 14, 2024
chaudhuri bhaskar
acquired
-
-
10,139
-
Jun 14, 2024
gilbert halley e
acquired
-
-
10,139
-
Jun 14, 2024
heron patrick j
acquired
-
-
10,139
-
Jun 14, 2024
krishnamohan neha
acquired
-
-
10,139
-
Jun 14, 2024
leonard keith r
acquired
-
-
10,139
-

1–10 of 50

Which funds bought or sold ARQT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
SG Americas Securities, LLC
added
531
766,000
922,000
-%
Jul 12, 2024
Koshinski Asset Management, Inc.
sold off
-100
-198,200
-
-%
Jul 10, 2024
CWM, LLC
added
6,740
37,000
38,000
-%
Jul 09, 2024
MATHER GROUP, LLC.
unchanged
-
1,269
1,883
-%
Jul 02, 2024
GAMMA Investing LLC
added
0.38
-602
9,784
-%
Jul 02, 2024
Park Place Capital Corp
unchanged
-
-112
1,702
-%
Jul 01, 2024
Legal & General Group Plc
reduced
-2.65
54,821
82,411
-%
Jun 21, 2024
Cape Investment Advisory, Inc.
sold off
-100
-25,853
-
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
881,000
1,343,000
-%
May 29, 2024
Opaleye Management Inc.
sold off
-100
-6,330,800
-
-%

1–10 of 48

Are Funds Buying or Selling ARQT?

Are funds buying ARQT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARQT
No. of Funds

Unveiling Arcutis Biotherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 06, 2024
jennison associates llc
10.8%
12,128,533
SC 13G/A
Mar 06, 2024
frazier life sciences viii, l.p.
7.8%
8,785,284
SC 13D/A
Feb 14, 2024
prudential financial inc
10.47%
0
SC 13G/A
Feb 13, 2024
polar capital holdings plc
6.67%
6,297,688
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
9.99%
9,534,837
SC 13G/A
Feb 13, 2024
vanguard group inc
5.19%
4,896,513
SC 13G
Feb 12, 2024
morgan stanley
6.5%
6,093,497
SC 13G
Feb 12, 2024
rubric capital management lp
7.04%
6,644,530
SC 13G
Feb 08, 2024
jennison associates llc
9.6%
9,066,082
SC 13G
Jan 31, 2024
point72 asset management, l.p.
5.1%
4,836,116
SC 13G

Recent SEC filings of Arcutis Biotherapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 02, 2024
4
Insider Trading
Jul 01, 2024
144
Notice of Insider Sale Intent
Jun 26, 2024
144
Notice of Insider Sale Intent
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
8-K
Current Report
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading

Peers (Alternatives to Arcutis Biotherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Arcutis Biotherapeutics Inc News

Latest updates
Defense World3 hours ago
Simply Wall St17 Jul 202406:11 pm
Yahoo Finance17 Jul 202401:54 pm
American Banking and Market News11 Jul 202410:34 am
Nasdaq28 Jun 202407:00 am

Arcutis Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Revenue266.5%50.0014.0038.005.003.002.001.00
Cost Of Revenue---1.001.001.000.000.00
Costs and Expenses-81.00---79.00--
Operating Expenses---75.0072.0079.0071.00105
  S&GA Expenses12.6%55.0049.0048.0046.0043.0037.0035.00
  R&D Expenses-2.7%23.0024.0026.0025.0035.0054.0030.00
Interest Expenses-3.6%7.008.008.007.007.007.005.00
Income Taxes2392.3%0.000.003.00----
Net Income46.6%-35.38-66.28-44.76-70.99-80.10-72.02-107
Net Income Margin53.5%-2.04*-4.40*-5.87*-10.45*-18.52*-84.50*-
Free Cashflow43.8%-31.60-56.25-44.05-66.76-80.43-71.19-67.70
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets40.2%479341293321379449509300364408387433471298198232254107
  Current Assets41.7%468330282309368437497295359403382428466293194228254106
    Cash Equivalents113.5%19189.0010710582.0055.0083.0063.0071.0098.0053.0091.0029067.0046.0017219163.00
  Inventory0.9%13.0013.0014.0010.009.008.004.00-----------
  Net PPE-11.0%1.002.002.002.002.002.002.002.002.002.002.002.002.002.000.000.000.000.00
Liabilities0.4%25425324624024024023810511011024.0018.0020.0028.0025.0023.0013.006.00
  Current Liabilities1.4%47.0047.0042.0037.0037.0038.0037.0027.0033.0033.0019.0013.0015.0023.0021.0019.0012.005.00
  Long Term Debt0.5%20320220120019919819773.0073.0072.00--------
    LT Debt, Non Current0.5%20320220120019919819773.0073.0072.00--------
Shareholder's Equity153.7%22589.0047.0081.00140210271195254298363414451271173209242-
  Retained Earnings-3.6%-1,017-981-915-870-799-719-647-540-472-408-336-280-238-201-167-129-94.30-66.30
  Additional Paid-In Capital16.0%1,2421,0719639529409309207377277067006956894733413393361.00
Shares Outstanding19.3%11697.0062.0062.0061.0061.0057.0051.0051.0049.0049.0050.00------
Float----487---878---1,082---620--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations43.8%-31,603-56,244-43,984-66,485-80,344-71,065-67,695-61,980-56,975-51,709-40,884-35,831-46,203-32,571-33,691-25,761-21,010-16,797-10,722-8,243-7,074
  Share Based Compensation14.5%10,0308,7579,99910,5789,4799,2648,7898,0966,5335,6865,3634,3408,5032,6432,2612,04999045515413976.00
Cashflow From Investing53.9%-28,697-62,18645,54989,118107,75142,201-197,26252,56515,29723,4993,471-164,91961,996-75,892-91,7116,105-20,326-35,99921,096-2,152-9,270
Cashflow From Financing62.9%161,76499,2898671,067100962284,9891,13114,71672,88163.001,188207,815129,380-437309168,89392,955-20.00168-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ARQT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 21,569$ 2,781
Other revenue28,0000
Total revenues49,5692,781
Operating expenses:  
Cost of sales3,256783
Research and development23,14135,345
Selling, general, and administrative54,79442,918
Total operating expenses81,19179,046
Loss from operations(31,622)(76,265)
Other income (expense):  
Other income, net4,0443,207
Interest expense(7,480)(7,042)
Loss before income taxes(35,058)(80,100)
Provision for income taxes3240
Net loss(35,382)(80,100)
Other comprehensive income (loss):  
Unrealized income (loss) on marketable securities(116)724
Foreign currency translation adjustment(21)(52)
Total other comprehensive income (loss)(137)672
Comprehensive loss$ (35,519)$ (79,428)
Per share information:  
Net loss per share, basic (in USD per share)$ (0.32)$ (1.31)
Net loss per share, diluted (in USD per share)$ (0.32)$ (1.31)
Weighted-average shares used in computing net loss per share, basic (in shares)111,048,52561,169,089
Weighted-average shares used in computing net loss per share, diluted (in shares)111,048,52561,169,089

ARQT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 190,097$ 88,398
Restricted cash617925
Marketable securities213,769183,463
Trade receivables, net37,15425,807
Inventories13,24713,134
Prepaid expenses and other current assets13,17818,704
Total current assets468,062330,431
Property, plant, and equipment, net1,3691,539
Intangible assets, net6,2506,438
Operating lease right-of-use asset2,2642,361
Other assets596596
Total assets478,541341,365
Current liabilities:  
Accounts payable12,96911,992
Accrued liabilities33,58433,941
Operating lease liability756735
Total current liabilities47,30946,668
Operating lease liability, noncurrent3,1813,382
Long-term debt, net202,803201,799
Other long-term liabilities306849
Total liabilities253,599252,698
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 115,505,437 and 96,787,343 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively129
Additional paid-in capital1,242,3491,070,558
Accumulated other comprehensive loss(133)4
Accumulated deficit(1,017,286)(981,904)
Total stockholders’ equity224,94288,667
Total liabilities and stockholders’ equity$ 478,541$ 341,365
ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
 CEO
 WEBSITEarcutis.com
 INDUSTRYBiotechnology
 EMPLOYEES268

Arcutis Biotherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Arcutis Biotherapeutics Inc? What does ARQT stand for in stocks?

ARQT is the stock ticker symbol of Arcutis Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcutis Biotherapeutics Inc (ARQT)?

As of Fri Jul 19 2024, market cap of Arcutis Biotherapeutics Inc is 1.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers. The fair value of Arcutis Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcutis Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARQT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcutis Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ARQT is over valued or under valued. Whether Arcutis Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Arcutis Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARQT.

What is Arcutis Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, ARQT's PE ratio (Price to Earnings) is -5.19 and Price to Sales (PS) ratio is 10.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARQT PE ratio will change depending on the future growth rate expectations of investors.